256 related articles for article (PubMed ID: 29843820)
21. [Treatment of advanced Hodgkin lymphoma].
Kreissl S; Borchmann P
Dtsch Med Wochenschr; 2013 Jun; 138(23):1212-4. PubMed ID: 23720173
[No Abstract] [Full Text] [Related]
22. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
23. [Treatment strategy of Hodgkin lymphoma].
Nagai H
Rinsho Ketsueki; 2014 Oct; 55(10):1941-51. PubMed ID: 25297759
[No Abstract] [Full Text] [Related]
24. Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report.
Zhu C; Zhao Y; Yu F; Huang W; Wu W; He J; Cai Z; He D
Front Immunol; 2021; 12():756583. PubMed ID: 35095839
[TBL] [Abstract][Full Text] [Related]
25. Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report.
Gunes AK; Demir I; Pehlivan M
J Oncol Pharm Pract; 2021 Mar; 27(2):509-512. PubMed ID: 32762294
[TBL] [Abstract][Full Text] [Related]
26. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
Wang E; Papavassiliou P; Sebastian S
Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037
[TBL] [Abstract][Full Text] [Related]
27. Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
Fizesan M; Boin C; Aujoulat O; Newinger G; Ghergus D; Watier H; Lustig H; Ojeda-Uribe M
J Oncol Pharm Pract; 2016 Feb; 22(1):188-92. PubMed ID: 25586990
[No Abstract] [Full Text] [Related]
28. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
30. Evolving approaches to primary treatment of Hodgkin lymphoma.
Connors JM
Hematology Am Soc Hematol Educ Program; 2005; ():239-44. PubMed ID: 16304387
[TBL] [Abstract][Full Text] [Related]
31. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
[TBL] [Abstract][Full Text] [Related]
32. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).
Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M
Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524
[TBL] [Abstract][Full Text] [Related]
33. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
34. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
35. A case with Hodgkin lymphoma and fronto-temporal lobular degeneration (FTLD)-like dementia facilitated by chemotherapy.
Katsumata R; Sagawa R; Akechi T; Shinagawa Y; Nakaaki S; Inagaki A; Okuyama T; Akazawa T; Furukawa TA
Jpn J Clin Oncol; 2010 Apr; 40(4):365-8. PubMed ID: 20026458
[TBL] [Abstract][Full Text] [Related]
36. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
38. The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced hodgkin lymphoma.
Gobbi PG; Rosti V; Valentino F; Bonetti E; Merli F; Stelitano C; Dondi A; Quarta G; Falorio S; Federico M
Clin Lymphoma Myeloma; 2009 Dec; 9(6):425-9. PubMed ID: 19951881
[TBL] [Abstract][Full Text] [Related]
39. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
40. A successful initiation of treatment of Hodgkin's lymphoma with adriamycin-bleomycin-vinblastine-dacarbazine dose reduction in a patient with fulminant hepatic failure and co-infection with human immunodeficiency virus and hepatitis B.
Veeraballi S; Chan KH; Slim J; Shaaban HS; Guron G
J Oncol Pharm Pract; 2022 Mar; 28(2):479-485. PubMed ID: 34590528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
